PRLD — Prelude Therapeutics Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1678660 ·
Last close
$4.60
Market Cap
$298.62M
52W High
$5.69
52W Low
$3.40
ADV30
523,911
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,580,000 | — | -14,177,000 | -10,385,000 | 119,642,000 | 21,756,000 | 59,459,000 |
| Dec 2025 | 5,640,000 | — | -17,348,000 | -16,457,000 | 141,315,000 | 35,256,000 | 72,678,000 |
| Sep 2025 | 6,500,000 | — | -20,418,000 | -19,725,000 | 94,755,000 | 47,532,000 | 36,221,000 |
| Jun 2025 | 0 | — | -32,194,000 | -31,231,000 | 114,918,000 | 25,752,000 | 39,080,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,756,000
Investing CF
$-228,000
Financing CF
$24,662,000
CapEx
$-183,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.22
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-693,446,000
Inventory
—
Receivables
—
ST Investments
$59,798,000
EBIT TTM
$-84,137,000
Pretax Income TTM
$-77,798,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$16,720,000
EBITDA
$-81,170,000
Free Cash Flow
$-17,930,124
Enterprise Value
$437,013,344
Total Cash
$81,554,000
Total Debt
$17,721,000
Shares Out
64,917,172
Trailing EPS
$-1.00
Book Value
$0.73
ROE
-95.2%
ROA
-39.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,140,000 | -104,566,000 | -99,498,000 | 141,315,000 | 72,678,000 | — | -56,302,000 |
| Dec 2024 | 7,000,000 | -139,714,000 | -127,173,000 | 175,515,000 | 44,056,000 | — | -102,888,000 |
| Dec 2023 | 0 | -132,277,000 | -121,832,000 | 277,665,000 | 40,575,000 | — | -107,063,000 |
| Dec 2022 | 0 | -123,540,000 | -115,438,000 | 220,500,000 | 25,063,000 | — | -83,729,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.86
Max Pain — expiry 2026-08-21
max pain strike: $5.00 · spot: $4.60 · call oi: 1,049 · put oi: 868
Expected Move to 2026-08-21:
±$1.25
(27.17%) —
implied range
$3.35 –
$5.85
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMRN | AMARIN CORP PLC\UK | $299.02M | $14.26 | — |
| LYEL | Lyell Immunopharma, Inc. | $301.94M | $12.94 | — |
| ORGO | Organogenesis Holdings Inc. | $304.96M | $2.37 | — |
| IRD | Opus Genetics, Inc. | $306.32M | $3.71 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $306.69M | $5.10 | — |
News headlines (Yahoo Finance, 1h cache)
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
2026-07-17 16:00 · Yahoo
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
2026-05-31 10:55 · Yahoo
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
2026-05-16 14:22 · Yahoo
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 11:01 · Yahoo
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
2026-05-08 13:55 · Yahoo
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
2026-05-01 09:24 · Yahoo
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cance
2026-04-20 10:00 · Yahoo
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
2026-04-15 11:30 · Yahoo
Myriad Genetics And 2 Other Penny Stocks To Watch Closely
2026-04-06 18:05 · Yahoo
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
2026-03-17 20:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.